Alkermes chief executive Richard Pops, who heads the company has just bought Elan's drug technology unit, has expressed confidence that the firm is agile enough to innovate.
In an interview published in the Irish Independent, Pops said he was conformatble with the debt level in the company following the takeover.
He described the company as "small and agile enough that we still have that entrepreneurial biotech culture that leads to innovation."
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team